Molecular approaches toward a therapy for multiple sclerosis.
Treatment of experimental allergic encephalomyelitis with monoclonal antibodies to products of immune response genes and to surface markers on T cells was reviewed. Both anti Ia therapy and anti T4 therapy can reverse ongoing paralysis, and block subsequent relapses. The appearance of T4 cells and Ia antigens in relapse was demonstrated. The prospects for human therapy with chimeric human-mouse immunoglobulins and isotypic variants was discussed, with particular attention to the immunotherapy of multiple sclerosis.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000628:therapy; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000628:therapy*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II